Our previous study demonstrates that the expression of Anxa2 increases when breast cancer MCF-7 cells acquire drug resistance (P-gp-over-expressing adriamycin-resistant breast cancer cells, denoted as MCF-7/ADR) [7]. Here, ANXA2 is linked to breast carcinoma.